G6PD Deficiency

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is an inherited metabolic disorder characterized by an enzyme defect that causes red blood cells (RBCs) to break down prematurely (hemolysis) when subjected to oxidative stress. It is the most common enzyme deficiency in humans, affecting approximately 400 million people worldwide. While many individuals remain asymptomatic, exposure to certain foods, medications, or infections can trigger acute hemolytic anemia.

G6PD deficiency is caused by mutations in the G6PD gene located on the X chromosome (Xq28). It follows an X-linked recessive inheritance pattern, meaning it primarily affects males, while females are typically carriers (though they can be affected due to skewed X-inactivation). The deficiency is categorized into classes (I-V) by the World Health Organization based on the severity of the enzyme deficiency and the resulting clinical symptoms.

The G6PD enzyme is the rate-limiting step in the pentose phosphate pathway, which produces nicotinamide adenine dinucleotide phosphate (NADPH). In RBCs, NADPH is essential for maintaining a pool of reduced glutathione, which protects cells against oxidative damage from reactive oxygen species (ROS). When G6PD is deficient, oxidative stress leads to the oxidation of hemoglobin, forming insoluble precipitates called Heinz bodies. These damage the RBC membrane, leading to splenic sequestration and hemolysis (both intravascular and extravascular).

The condition is most prevalent in populations from sub-Saharan Africa, the Mediterranean, the Middle East, and Southeast Asia. This distribution closely parallels areas where malaria was historically endemic, as G6PD deficiency provides a selective survival advantage against Plasmodium falciparum malaria.

• Gender: Males (X-linked inheritance).
• Ethnicity: African, Mediterranean, or Asian descent.
• Family History: Known G6PD deficiency in the lineage.
• Specific Triggers: Exposure to fava beans, naphthalene (mothballs), or oxidizing medications.

• Vital Signs: Tachycardia, tachypnea, and occasionally hypotension in severe cases.
• Inspection: Scleral icterus, cutaneous jaundice, and pale conjunctivae.
• Palpation: Splenomegaly may be noted in the left upper quadrant.
• Auscultation: A flow murmur (hemic murmur) may be heard due to the hyperdynamic state of anemia.

Quantitative G6PD Assay
Type: Blood Test
Purpose: Measure the level of G6PD enzyme activity in RBCs.
Expected Findings: Low enzyme activity levels.
Interpretation: Confirms diagnosis; levels must be measured outside of an acute hemolytic episode to avoid false negatives. Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess hemoglobin levels and RBC indices.
Expected Findings: Decreased hemoglobin/hematocrit during episodes.
Interpretation: Indicates the severity of the anemia. Peripheral Blood Smear
Type: Microscopic Examination
Purpose: Visualize cell morphology.
Expected Findings: Heinz bodies (with crystal violet stain) and "bite cells" or "blister cells."
Interpretation: Hallmark signs of oxidative damage to RBCs.

• Abdominal Ultrasound: Used to evaluate for splenomegaly and cholelithiasis (gallstones) resulting from chronic low-grade hemolysis. Typical findings include an enlarged spleen or gallstones in the gallbladder.

• Hereditary Spherocytosis: Characterized by spherical RBCs and positive osmotic fragility test, without G6PD triggers.
• Autoimmune Hemolytic Anemia: Distinguished by a positive Direct Antiglobulin (Coombs) test.
• Sickle Cell Anemia: Identified by hemoglobin electrophoresis showing HbS.

• Acute Kidney Injury (AKI): Caused by hemoglobinuria blocking renal tubules.
• Kernicterus: Severe jaundice in newborns leading to brain damage if untreated.
• Gallstones: Chronic hemolysis can lead to bilirubin stone formation.

The prognosis is excellent if triggers are avoided. Most individuals have a normal life expectancy. Hemolytic episodes are usually self-limiting as the body clears damaged cells and produces new ones.

Primary prevention involves genetic counseling. Secondary prevention involves screening newborns in high-risk populations and providing "safe/unsafe" drug lists to diagnosed individuals.

The following homeopathic remedies have been historically indicated for symptoms associated with G6PD Deficiency. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to G6PD Deficiency.